Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Anish Maru"'
3
Report of chronic myeloid leukemia from SEAROC experience, Jaipur over a period of 9 years
Autor: Anish Maru
Publikováno v: Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology
SEAROC cancer center presented the data 387 patients from the city of Jaipur. This oncology center caters large number of population from Jaipur as well as from neighboring states. Out of the 387 patients, 334 (86%) patients were in chronic phase. Co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45a54ce23737dff40b21a8228e17955
https://pubmed.ncbi.nlm.nih.gov/24516304
Zobrazit plný text záznamu
4
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE
Autor: Fausto Roila, Anish Maru, Judith A. Boice, Suzanne DeVandry, Alexandra D. Carides, Elizabeth Beckford, Steven M. Grunberg, José Dinis, Arlene Taylor, James S. Hardwick, Jørn Herrstedt, Daniel Chua
Publikováno v: Grunberg, S, Chua, D, Maru, A, Dinis, J, DeVandry, S, Boice, J A, Hardwick, J S, Beckford, E, Taylor, A, Carides, A, Roila, F & Herrstedt, J 2011, ' Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE ', Journal of Clinical Oncology, vol. 29, no. 11, pp. 1495-501 . https://doi.org/10.1200/JCO.2010.31.7859
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours). T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e39a05fb3723d242ff10074221c75771
https://pubmed.ncbi.nlm.nih.gov/21383291
Zobrazit plný text záznamu
6
P-0133 Long Term Follow up of Managing Patients with Metastatic Gastrointestinal Stromal Tumour with Imatinib Mesylate at an Indian Centre
Autor: Dinesh Mangal, Anish Maru, Vijay Sharma
Publikováno v: Annals of Oncology. 23:iv69
Introduction Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Most commonly originate in the stomach and small intestine. One third of high risk, malignant GIST have poor prognosis after
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bae85294835226e9f736f930d09c9f2e
https://doi.org/10.1016/s0923-7534(20)30053-3
Zobrazit plný text záznamu
7
P-0009 Palliative Esophageal Metal Stenting Under Endoscopic Guidance Without the Use of Fluoroscopy: Initial Experience at an Indian Centre
Autor: Anish Maru, Vijay Sharma, Dinesh Mangal
Publikováno v: Annals of Oncology. 23:iv33
Introduction Esophageal carcinoma is a common cancer, many patients require palliative metal stenting. Fluoroscopy is not available in every endoscopy unit, this situation leads to delay in treatment or to transfer to other centres for metal stent in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0d94ec1e9378cd611888f5564b77d4b
https://doi.org/10.1016/s0923-7534(20)30016-8
Zobrazit plný text záznamu
8
A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors
Autor: Minish Mahendra Jain, Nitin Jadhav, Shona Nag, Shivani Anil Acharya, Anish Maru, Sujay Kulkarni, Poornima Dhobe, Sudeep Gupta, Naresh Somani, Ajay O. Mehta
Publikováno v: Journal of Clinical Oncology. 30:3011-3011
3011 Background: Cyclin-dependent kinases (Cdks) have emerged as important targets in anticancer drug development. P1446A-05 is a potent and specific inhibitor of Cdk4-D1 (IC50-0.09µM), Cdk1-B (IC50-0.025µM), and Cdk9-T (IC50-0.022µM). This study
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef8d03041b371df46bf63d1876850cdf
https://doi.org/10.1200/jco.2012.30.15_suppl.3011
Zobrazit plný text záznamu
9
Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up
Autor: Anish Maru, François Guilhot, Jorge E. Cortes, Carmino Antonio De Souza, Ladan Duvillie, Athena Countouriotis, Christine Powell, Carlo Gambacorti-Passerini
Publikováno v: Blood. 118:455-455
Abstract 455 Introduction: Bosutinib (SKI-606) is an orally active, dual competitive inhibitor of the Src and Abl tyrosine kinases. The phase 3 BELA study compared bosutinib with imatinib in patients (pts) with newly diagnosed chronic phase (CP) chro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df35d5ec9189709f550ef90d9662ca9f
https://doi.org/10.1182/blood.v118.21.455.455
Zobrazit plný text záznamu
10
Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting
Autor: James S. Hardwick, Alexandra D. Carides, D. T. Chua, Anish Maru, Jørn Herrstedt, Fausto Roila, Suzanne DeVandry, Arlene Taylor, Judith A. Boice, Steven M. Grunberg
Publikováno v: Journal of Clinical Oncology. 28:9021-9021
9021^ Background: Addition of a neurokinin-1 antagonist (NK1A) to a standard ondansetron (O) and dexamethasone (D) antiemetic regimen improves prevention of cisplatin-induced nausea/vomiting (CINV)...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad56b903ec01a054a809ce113b0fe37c
https://doi.org/10.1200/jco.2010.28.15_suppl.9021
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje